1Sheil AG, Sun J, Mears DC, et al. Positive biochemical effects of a bioartificial liver support system (BALSS) in a poreine fulminant hepatic failure (FHF) model. Int J Artif Organs, 1998,21 :43-48.
2Manzin A, Candela M, Solforosi L, et al. Dynamics of hepatitis C viremia after plasma exchange. J Hepatol, 1999, 31:389-393.
3Nakamura T, Ushiyama C, Suzuki S, et al. Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis.Blood Purif, 2000, 18:50-54.
4De Silvestro G, Marson P, Brandolese R, et al. A single institution's experience (1982-1999) with plasma-exchange therapy in patients with fulminant hepatic failure. Int J Artif Organs,2000, 23:454-461.
5Masuhara M, Yagawa T, Aoyagi M, et al. HBV-related fulminant hepatic failure: successful intensive medical therapy in a candidate for liver transplantation. J Gastroenterol, 2001, 36:350-353.
9Yao FY,Terrault NA,Freise C,et al.Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:a comparative study using a matched,untreated cohort.Hepatolqgy.2001,34:411-416.
10Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:a comparative study using a matched,untreated cohort [J]. Hepatology ,2001,34:411-416.
